• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

EBV 微小 RNA BART11 和 BART17-3p 通过增强子介导的 PD-L1 转录促进免疫逃逸。

EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.

机构信息

NHC Key Laboratory of Carcinogenesis and Hunan Key Laboratory of Cancer Metabolism, Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, China.

Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute and School of Basic Medicine Sciences, Central South University, Changsha, Hunan, China.

出版信息

Nat Commun. 2022 Feb 14;13(1):866. doi: 10.1038/s41467-022-28479-2.

DOI:10.1038/s41467-022-28479-2
PMID:35165282
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8844414/
Abstract

Epstein-Barr virus (EBV) is reportedly the first identified human tumor virus, and is closely related to the occurrence and development of nasopharyngeal carcinoma (NPC), gastric carcinoma (GC), and several lymphomas. PD-L1 expression is elevated in EBV-positive NPC and GC tissues; however, the specific mechanisms underlying the EBV-dependent promotion of PD-L1 expression to induce immune escape warrant clarification. EBV encodes 44 mature miRNAs. In this study, we find that EBV-miR-BART11 and EBV-miR-BART17-3p upregulate the expression of PD-L1 in EBV-associated NPC and GC. Furthermore, EBV-miR-BART11 targets FOXP1, EBV-miR-BART17-3p targets PBRM1, and FOXP1 and PBRM1 bind to the enhancer region of PD-L1 to inhibit its expression. Therefore, EBV-miR-BART11 and EBV-miR-BART17-3p inhibit FOXP1 and PBRM1, respectively, and enhance the transcription of PD-L1 (CD274, http://www.ncbi.nlm.nih.gov/gene/29126 ), resulting in the promotion of tumor immune escape, which provides insights into potential targets for EBV-related tumor immunotherapy.

摘要

EB 病毒（EBV）据报道是第一个被发现的人类肿瘤病毒，与鼻咽癌（NPC）、胃癌（GC）和几种淋巴瘤的发生和发展密切相关。PD-L1 在 EBV 阳性 NPC 和 GC 组织中表达上调；然而，需要阐明 EBV 依赖性促进 PD-L1 表达以诱导免疫逃逸的具体机制。EBV 编码 44 个成熟的 miRNA。在本研究中，我们发现 EBV-miR-BART11 和 EBV-miR-BART17-3p 上调 EBV 相关 NPC 和 GC 中 PD-L1 的表达。此外，EBV-miR-BART11 靶向 FOXP1，EBV-miR-BART17-3p 靶向 PBRM1，FOXP1 和 PBRM1 结合到 PD-L1 的增强子区域抑制其表达。因此，EBV-miR-BART11 和 EBV-miR-BART17-3p 分别抑制 FOXP1 和 PBRM1，并增强 PD-L1（CD274，http://www.ncbi.nlm.nih.gov/gene/29126）的转录，从而促进肿瘤免疫逃逸，为 EBV 相关肿瘤免疫治疗提供了潜在靶点。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/929d5e3ff636/41467_2022_28479_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/df8b8215f636/41467_2022_28479_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/b53c1531fe7d/41467_2022_28479_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/f0729f634102/41467_2022_28479_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/e25f1482904c/41467_2022_28479_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/cfd8b073925e/41467_2022_28479_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/18835454c368/41467_2022_28479_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/a162cdf0aac0/41467_2022_28479_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/9282076e618a/41467_2022_28479_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/60f3b7037c81/41467_2022_28479_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/929d5e3ff636/41467_2022_28479_Fig10_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/df8b8215f636/41467_2022_28479_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/b53c1531fe7d/41467_2022_28479_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/f0729f634102/41467_2022_28479_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/e25f1482904c/41467_2022_28479_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/cfd8b073925e/41467_2022_28479_Fig5_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/18835454c368/41467_2022_28479_Fig6_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/a162cdf0aac0/41467_2022_28479_Fig7_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/9282076e618a/41467_2022_28479_Fig8_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/60f3b7037c81/41467_2022_28479_Fig9_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b69f/8844414/929d5e3ff636/41467_2022_28479_Fig10_HTML.jpg

相似文献

1
EBV miRNAs BART11 and BART17-3p promote immune escape through the enhancer-mediated transcription of PD-L1.EBV 微小 RNA BART11 和 BART17-3p 通过增强子介导的 PD-L1 转录促进免疫逃逸。
Nat Commun. 2022 Feb 14;13(1):866. doi: 10.1038/s41467-022-28479-2.
2
Epstein-Barr virus encoded miR-BART11 promotes inflammation-induced carcinogenesis by targeting FOXP1.爱泼斯坦-巴尔病毒编码的miR-BART11通过靶向FOXP1促进炎症诱导的致癌作用。
Oncotarget. 2016 Jun 14;7(24):36783-36799. doi: 10.18632/oncotarget.9170.
3
Epstein-Barr virus-encoded miR-BART11 promotes tumor-associated macrophage-induced epithelial-mesenchymal transition via targeting FOXP1 in gastric cancer.EB 病毒编码的 miR-BART11 通过靶向 FOXP1 促进肿瘤相关巨噬细胞诱导的胃癌上皮-间充质转化。
Virology. 2020 Sep;548:6-16. doi: 10.1016/j.virol.2020.05.011. Epub 2020 Jun 2.
4
EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinoma.EBV 编码的 microRNAs 靶向鼻咽癌中的 ATM 介导的反应。
J Pathol. 2018 Apr;244(4):394-407. doi: 10.1002/path.5018. Epub 2018 Feb 16.
5
Epstein-Barr virus-encoded miR-BART5-5p upregulates PD-L1 through PIAS3/pSTAT3 modulation, worsening clinical outcomes of PD-L1-positive gastric carcinomas.EB 病毒编码的 miR-BART5-5p 通过 PIAS3/pSTAT3 调节上调 PD-L1，使 PD-L1 阳性胃癌的临床预后恶化。
Gastric Cancer. 2020 Sep;23(5):780-795. doi: 10.1007/s10120-020-01059-3. Epub 2020 Mar 23.
6
EBV-miR-BART10-3p facilitates epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma by targeting BTRC.EBV-miR-BART10-3p通过靶向BTRC促进上皮-间质转化并推动鼻咽癌转移。
Oncotarget. 2015 Dec 8;6(39):41766-82. doi: 10.18632/oncotarget.6155.
7
Epstein-Barr virus-encoded miR-BART6-3p inhibits cancer cell proliferation through the LOC553103-STMN1 axis. Epstein-Barr 病毒编码的 miR-BART6-3p 通过 LOC553103-STMN1 轴抑制癌细胞增殖。
FASEB J. 2020 Jun;34(6):8012-8027. doi: 10.1096/fj.202000039RR. Epub 2020 Apr 18.
8
Detection of Epstein-Barr virus (EBV)-encoded microRNAs in plasma of patients with nasopharyngeal carcinoma.检测鼻咽癌患者血浆中的 Epstein-Barr 病毒 (EBV) 编码 microRNAs。
Head Neck. 2019 Mar;41(3):780-792. doi: 10.1002/hed.25544. Epub 2018 Dec 13.
9
Epstein-Barr Virus MicroRNA miR-BART5-3p Inhibits p53 Expression.EB 病毒 microRNA miR-BART5-3p 抑制 p53 表达。
J Virol. 2018 Nov 12;92(23). doi: 10.1128/JVI.01022-18. Print 2018 Dec 1.
10
EBV-miR-BART8-3p induces epithelial-mesenchymal transition and promotes metastasis of nasopharyngeal carcinoma cells through activating NF-κB and Erk1/2 pathways.EBV-miR-BART8-3p 通过激活 NF-κB 和 Erk1/2 通路诱导鼻咽癌细胞上皮-间充质转化并促进其转移。
J Exp Clin Cancer Res. 2018 Nov 26;37(1):283. doi: 10.1186/s13046-018-0953-6.

引用本文的文献

1
Microbiome meets immunotherapy: unlocking the hidden predictors of immune checkpoint inhibitors.微生物组与免疫疗法相遇：揭开免疫检查点抑制剂的隐藏预测指标
NPJ Biofilms Microbiomes. 2025 Sep 2;11(1):180. doi: 10.1038/s41522-025-00819-2.
2
Integrating pan-immune-inflammation value into personalized survival prediction of nasopharyngeal carcinoma: a large-scale long-term retrospective study.将泛免疫炎症值纳入鼻咽癌个性化生存预测：一项大规模长期回顾性研究
BMC Cancer. 2025 Jul 21;25(1):1194. doi: 10.1186/s12885-025-14413-4.
3
Development and validation of an ARID1A-related immune genes risk model in evaluating prognosis and immune therapeutic efficacy for gastric cancer patients: a translational study.

本文引用的文献

1
Epstein-Barr Virus-Encoded Circular RNA CircBART2.2 Promotes Immune Escape of Nasopharyngeal Carcinoma by Regulating PD-L1. Epstein-Barr 病毒编码的环状 RNA CircBART2.2 通过调节 PD-L1 促进鼻咽癌的免疫逃逸。
Cancer Res. 2021 Oct 1;81(19):5074-5088. doi: 10.1158/0008-5472.CAN-20-4321. Epub 2021 Jul 28.
2
Cancer SLC43A2 alters T cell methionine metabolism and histone methylation.癌症 SLC43A2 改变 T 细胞蛋氨酸代谢和组蛋白甲基化。
Nature. 2020 Sep;585(7824):277-282. doi: 10.1038/s41586-020-2682-1. Epub 2020 Sep 2.
3
Single cell RNA-seq reveals the landscape of tumor and infiltrating immune cells in nasopharyngeal carcinoma.
ARID1A相关免疫基因风险模型在评估胃癌患者预后及免疫治疗疗效中的开发与验证：一项转化研究
Front Immunol. 2025 Apr 28;16:1541491. doi: 10.3389/fimmu.2025.1541491. eCollection 2025.
4
HBV sequence integrated to enhancer acting as oncogenic driver epigenetically promotes hepatocellular carcinoma development.整合到增强子的乙肝病毒序列作为致癌驱动因子，通过表观遗传促进肝细胞癌发展。
J Exp Clin Cancer Res. 2025 May 22;44(1):155. doi: 10.1186/s13046-025-03413-8.
5
Harnessing Cellular Immunotherapy for EBV-Associated Malignancies: Current Advances and Future Directions.利用细胞免疫疗法治疗EB病毒相关恶性肿瘤：当前进展与未来方向
J Cell Mol Med. 2025 May;29(10):e70603. doi: 10.1111/jcmm.70603.
6
Viral oncogenesis in cancer: from mechanisms to therapeutics.癌症中的病毒致癌作用：从机制到治疗
Signal Transduct Target Ther. 2025 May 12;10(1):151. doi: 10.1038/s41392-025-02197-9.
7
Establishing a Risk Prediction Model for Nasopharyngeal Carcinoma Based on Anti-BNLF2b Serological Biomarkers: A Retrospective Study.基于抗BNLF2b血清学生物标志物建立鼻咽癌风险预测模型：一项回顾性研究。
Int J Med Sci. 2025 Apr 13;22(9):2165-2173. doi: 10.7150/ijms.110758. eCollection 2025.
8
Non-coding RNAs as potential mediators of resistance to lung cancer immunotherapy and chemotherapy.非编码RNA作为肺癌免疫治疗和化疗耐药性的潜在介导因子。
Oncol Res. 2025 Apr 18;33(5):1033-1054. doi: 10.32604/or.2024.058256. eCollection 2025.
9
Revealing the viral culprits: the hidden role of the oral virome in head and neck cancers.揭示病毒元凶：口腔病毒组在头颈癌中的隐藏作用。
Arch Microbiol. 2025 Feb 28;207(4):73. doi: 10.1007/s00203-025-04270-x.
10
Recent advances in the mechanisms of PD-L1 expression in gastric cancer: a review.胃癌中程序性死亡受体配体1（PD-L1）表达机制的最新进展：综述
Biol Res. 2025 Mar 17;58(1):16. doi: 10.1186/s40659-025-00597-3.
单细胞 RNA 测序揭示鼻咽癌中肿瘤和浸润免疫细胞的全景。
Cancer Lett. 2020 May 1;477:131-143. doi: 10.1016/j.canlet.2020.02.010. Epub 2020 Feb 13.
4
Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy.预测生物标志物和抗 PD1/PD-L1 阻断癌症免疫治疗的机制。
Mol Cancer. 2020 Jan 30;19(1):19. doi: 10.1186/s12943-020-1144-6.
5
A Tumor-Specific Super-Enhancer Drives Immune Evasion by Guiding Synchronous Expression of PD-L1 and PD-L2.肿瘤特异性超级增强子通过指导 PD-L1 和 PD-L2 的同步表达来驱动免疫逃逸。
Cell Rep. 2019 Dec 10;29(11):3435-3447.e4. doi: 10.1016/j.celrep.2019.10.093.
6
Analysis of status and countermeasures of cancer incidence and mortality in China.中国癌症发病与死亡分析及对策
Sci China Life Sci. 2019 May;62(5):640-647. doi: 10.1007/s11427-018-9461-5. Epub 2019 Mar 12.
7
Natural killer group 2D receptor and its ligands in cancer immune escape.自然杀伤细胞组 2D 受体及其配体在癌症免疫逃逸中的作用。
Mol Cancer. 2019 Feb 27;18(1):29. doi: 10.1186/s12943-019-0956-8.
8
Role of the tumor microenvironment in PD-L1/PD-1-mediated tumor immune escape.肿瘤微环境在 PD-L1/PD-1 介导的肿瘤免疫逃逸中的作用。
Mol Cancer. 2019 Jan 15;18(1):10. doi: 10.1186/s12943-018-0928-4.
9
Transcription factor Foxp1 regulates Foxp3 chromatin binding and coordinates regulatory T cell function.转录因子 Foxp1 调节 Foxp3 染色质结合并协调调节性 T 细胞功能。
Nat Immunol. 2019 Feb;20(2):232-242. doi: 10.1038/s41590-018-0291-z. Epub 2019 Jan 14.
10
The BAF and PRC2 Complex Subunits Dpf2 and Eed Antagonistically Converge on Tbx3 to Control ESC Differentiation.BAF 和 PRC2 复合物亚基 Dpf2 和 Eed 拮抗作用于 Tbx3 以控制 ESC 分化。
Cell Stem Cell. 2019 Jan 3;24(1):138-152.e8. doi: 10.1016/j.stem.2018.12.001.